Review anchor
Bone morphogenetic protein receptor type-2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Bone morphogenetic protein receptor type-2
CHEMBL5467
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Bone morphogenetic protein receptor type-2 as ChEMBL target CHEMBL5467, mapped to UniProt Q13873. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5467
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13873
Bone morphogenetic protein receptor type-2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Bone morphogenetic protein receptor type-2 matters
Bone morphogenetic protein receptor type-2 is reviewed as Bone morphogenetic protein receptor type-2 (UniProt Q13873); Bone morphogenetic protein receptor type-2 shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 577 compounds, and 163 assays, with lead potency reaching pChEMBL 8.5.
Protein context
Bone morphogenetic protein receptor type-2
Bone morphogenetic protein receptor type-2 Sequence length is 1038 aa.
Review this target as Bone morphogenetic protein receptor type-2, mapped to UniProt Q13873. Sequence length is 1038 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q13873
Protein
Disease context
bone disease
Bone morphogenetic protein receptor type-2 shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DIBOTERMIN ALFA, EPTOTERMIN ALFA.
Start review with bone disease because it currently carries approved-linked support. Linked drugs include DIBOTERMIN ALFA, EPTOTERMIN ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 6 approved drugs, 577 compounds, and 163 assays for this target. The dominant activity type is KD. CHEMBL400402 is the current potency anchor at pChEMBL 8.5.
Use CHEMBL400402 as the tractability anchor when discussing potency (pChEMBL 8.5).
Activity source · ChEMBL 36 via Core Engine
6 approved
pChEMBL 8.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Bone morphogenetic protein receptor type-2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13873, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why bone disease is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
577
Total Compounds
163
Total Assays
6
Approved Drugs
IC50: 41.0, KI: 24.0, KD: 370.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL400402
|
8.5 | Kd | — |
|
|
No preferred name
CHEMBL5404016
|
8.3 | Ki | — |
|
|
No preferred name
CHEMBL5404269
|
8.2 | Ki | — |
|
|
No preferred name
CHEMBL5422418
|
8.2 | Ki | — |
|
|
No preferred name
CHEMBL5434353
|
8.1 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DEUCRAVACITINIB
CHEMBL4435170
|
2022 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
Source Header